Research programme: rod-derived cone viability factor therapeutics - Fovea Pharmaceuticals

Drug Profile

Research programme: rod-derived cone viability factor therapeutics - Fovea Pharmaceuticals

Alternative Names: FOV 2501

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM; Novartis
  • Developer Fovea Pharmaceuticals
  • Class Proteins
  • Mechanism of Action TXNL6 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • Available For Licensing Yes - Eye disorders

Highest Development Phases

  • No development reported Retinitis pigmentosa

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in France (Intravitreous)
  • 14 Jul 2010 Preclinical development is ongoing in France
  • 14 Jul 2010 Recombinant human rod-derived cone viability factor is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top